AGENUS INC

AGENNASDAQ

🏆 #2749 by market capEarnings Nov 9US Equity

$409.81▼ $20.37 (−4.97%)

Simulated price

1h—

24h▼ 5.0%

7d—

14d—

30d—

1y—

🏦Market Cap

$307M

Small Cap

📈Revenue Growth (YoY)

+24.5%

Healthy

📊Gross Margin

99.3%

High

💵FCF Margin

88.0%

Strong

⚖️P/S Ratio

2.5x

Cheap

Otter Score

Weak

No chart data available for AGEN.

Trading Snapshot

Day Range: $405.61 – $414.58
52-Week Range: $2.71 – $8.85
Volume: $5.68B
Avg Volume: $4.50B
Shares Outstanding: 41.6M
Next Earnings: Sep 9, 2026

Fundamentals Snapshot

Annual Revenue: $114M
Last Q Revenue: $35M
P/E Ratio: 4.8
P/S Ratio: 2.5x
EPS (TTM): $1.67
Dividend Yield: —

Why Investors Own AGEN

✓High-growth profile — revenue up +0.3% YoY with expanding US Equity exposure.
✓Healthy economics — 53% gross margin and 28% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$114M▲ +2.2% YoY

Gross Margin (TTM)

53.0%▲ +1.4% YoY

Operating Income (TTM)

$33M▲ +2.2% YoY

Free Cash Flow (TTM)

$32M▲ +2.2% YoY

About AGENUS INC

Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.

🦦